Citizens Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $97

Benzinga Newsdesk www.benzinga.com Positive 91.7%

Neg 0% Neu 0% Pos 91.7%

Citizens analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and raises the price target from $96 to $97.